Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function
Masaaki Yamamoto, Anat Ben-Shlomo, Hiraku Kameda, Hidenori Fukuoka, Nan Deng, Yan Ding, Shlomo Melmed
Masaaki Yamamoto, Anat Ben-Shlomo, Hiraku Kameda, Hidenori Fukuoka, Nan Deng, Yan Ding, Shlomo Melmed
View: Text | PDF
Research Article Endocrinology

Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function

  • Text
  • PDF
Abstract

Pituitary corticotroph somatostatin receptor subtype 5 (SSTR5) signals to inhibit adrenocorticotrophin (ACTH) secretion. As ACTH deficiency results in attenuated adrenal cortisol production and an impaired stress response, we sought to clarify the role of SSTR5 in modifying the hypothalamic/pituitary/adrenal (HPA) axis. We generated Tg HP5 mice overexpressing SSTR5 in pituitary corticotrophs that produce the ACTH precursor proopiomelanocortin (POMC). Basal ACTH and corticosterone were similar in HP5 and WT mice, while HP5 mice showed attenuated ACTH and corticosterone responses to corticotrophin releasing hormone (CRH). HP5 mice exhibited attenuated corticosterone responses upon a restraint stress test and inflammatory stress following LPS injection, as well as increased anxiety-like and depressive-like behavior on open field and forced swim tests. Pituitary corticotroph CRH receptor subtype 1 (CRHR1) mRNA expression and ACTH responses to CRH were also attenuated in HP5 mice. In AtT20 cells stably overexpressing SSTR5, CRHR1 expression and cAMP response to CRH were reduced, whereas both were increased after SSTR5 KO. In elucidating mechanisms for these observations, we show that SSTR5-induced miR-449c suppresses both CRHR1 expression and function. We conclude that corticotroph SSTR5 attenuates HPA axis responses via CRHR1 downregulation, suggesting a role for SSTR5 in the pathogenesis of secondary adrenal insufficiency.

Authors

Masaaki Yamamoto, Anat Ben-Shlomo, Hiraku Kameda, Hidenori Fukuoka, Nan Deng, Yan Ding, Shlomo Melmed

×

Figure 6

SSTR5 suppresses corticotroph CRHR1 expression and signaling.

Options: View larger image (or click on image) Download as PowerPoint
SSTR5 suppresses corticotroph CRHR1 expression and signaling.
(A) mRNA e...
(A) mRNA expression levels determined by qPCR in primary pituitary cell culture (2 × 105 cells/well; n = 3) derived from SSTR2-KO mice administered no treatment (NT), pasireotide 1 nM, or octreotide 1 nM for 24 hours. (B–D) mRNA and protein expression in transgenic (Tg) AtT20/D16v-F2 cells stably expressing hSSTR5-IRES-ZsGreen and AtT20/D16v-F2 cells expressing only pZsGreen1-N1 (B) Crhr1 mRNA expression levels measured by qPCR (n = 3/group). (C) Western blot analysis of hSSTR5 and CRHR1 compared with β-tubulin. (D) Quantification analysis of CRHR1 normalized to β-tubulin. (E) mRNA levels of the indicated genes as expressed in SSTR5-KO AtT20 cell clones (KO#1–3) compared with cells that maintain intact SSTR5 (WT). (F) Western blot analysis of CRHR1 in WT and KO#1–3 cells compared with β-tubulin as loading control, and (G) quantification of CRHR1 normalized to β-tubulin in WT compared with KO#1–3 (n = 3/group). (H and I) Intracellular cAMP levels after treatment with increasing doses of CRH for 30 minutes in (H) hSSTR5-expressing AtT20 clones (Tg) and (I) KO#1 and KO#3 AtT20 clones compared with respective controls. Y axis represents fold change in cAMP from CRH-untreated cells (NT) measured with the LANCE cAMP assay. Samples contained 8.0 × 104 cells/well; n = 4 for each CRH concentration. Results are presented as mean ± SEM. Experiments were repeated in triplicate, and representative results are shown (H and I). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; 2-tailed unpaired t test, (H and I) with Bonferroni correction.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts